Elevated glutathione in researchers exposed to engineered nanoparticles due to potential adaptation to oxidative stress.

Nanomedicine (London, England) Pub Date : 2024-02-01 Epub Date: 2024-01-26 DOI:10.2217/nnm-2023-0207

Pavlina Klusackova, Lucie Lischkova, Viktoriia Kolesnikova, Tomas Navratil, Stepanka Vlckova, Zdenka Fenclova, Jaroslav Schwarz, Jakub Ondracek, Lucie Ondrackova, Martin Kostejn, Stepanka Dvorackova, Andrea Rossnerova, Miroslav Pohanka, Pavel Bradna, Vladimir Zdimal, Daniela Pelclova

{"title":"Elevated glutathione in researchers exposed to engineered nanoparticles due to potential adaptation to oxidative stress.","authors":"Pavlina Klusackova, Lucie Lischkova, Viktoriia Kolesnikova, Tomas Navratil, Stepanka Vlckova, Zdenka Fenclova, Jaroslav Schwarz, Jakub Ondracek, Lucie Ondrackova, Martin Kostejn, Stepanka Dvorackova, Andrea Rossnerova, Miroslav Pohanka, Pavel Bradna, Vladimir Zdimal, Daniela Pelclova","doi":"10.2217/nnm-2023-0207","DOIUrl":null,"url":null,"abstract":"Aim: To find a practical biomonitoring method for researchers exposed to nanoparticles causing oxidative stress. Methods: In a continuation of a study in 2016-2018, biological samples (plasma, urine and exhaled breath condensate [EBC]) were collected in 2019-2020 from 43 researchers (13.8 ± 3.0 years of exposure) and 45 controls. Antioxidant status was assessed using glutathione (GSH) and ferric-reducing antioxidant power, while oxidative stress was measured as thiobarbituric acid reactive substances, all using spectrophotometric methods. Researchers' personal nanoparticle exposure was monitored. Results: Plasma GSH was elevated in researchers both before and after exposure (p < 0.01); postexposure plasma GSH correlated with nanoparticle exposure, and GSH in EBC increased. Conclusion: The results suggest adaptation to chronic exposure to nanoparticles, as monitored by plasma and EBC GSH.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"185-198"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nnm-2023-0207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To find a practical biomonitoring method for researchers exposed to nanoparticles causing oxidative stress. Methods: In a continuation of a study in 2016-2018, biological samples (plasma, urine and exhaled breath condensate [EBC]) were collected in 2019-2020 from 43 researchers (13.8 ± 3.0 years of exposure) and 45 controls. Antioxidant status was assessed using glutathione (GSH) and ferric-reducing antioxidant power, while oxidative stress was measured as thiobarbituric acid reactive substances, all using spectrophotometric methods. Researchers' personal nanoparticle exposure was monitored. Results: Plasma GSH was elevated in researchers both before and after exposure (p < 0.01); postexposure plasma GSH correlated with nanoparticle exposure, and GSH in EBC increased. Conclusion: The results suggest adaptation to chronic exposure to nanoparticles, as monitored by plasma and EBC GSH.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

由于对氧化应激的潜在适应，暴露于工程纳米粒子的研究人员体内谷胱甘肽升高。

目的：为暴露于纳米粒子导致氧化应激的研究人员找到一种实用的生物监测方法。方法：作为 2016-2018 年研究的延续，2019-2020 年收集了 43 名研究人员（暴露年限为 13.8 ± 3.0 年）和 45 名对照组的生物样本（血浆、尿液和呼出气体冷凝物 [EBC]）。使用谷胱甘肽（GSH）和铁还原抗氧化能力评估抗氧化状态，使用硫代巴比妥酸活性物质测量氧化应激，所有方法均采用分光光度法。对研究人员的个人纳米粒子暴露进行了监测。结果研究人员在接触纳米粒子前后血浆 GSH 都有所升高（p 结论：研究人员在接触纳米粒子前后血浆 GSH 都有所升高：结果表明，通过监测血浆和 EBC GSH，研究人员可以适应长期接触纳米粒子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量

期刊最新文献

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Advances in Alzheimer's disease control approaches via carbon nanotubes. CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics. Correction. The emergence of inhalable RNA therapeutics and challenges faced - where to from here?